(MENAFN- GlobeNewsWire - Nasdaq) The Human Microbiome Market is thriving with opportunities in cancer treatment through microbiome-based therapies, enhanced by strategic industry partnerships and governmental support. Personalized medicine advancements offer tailored interventions, making the market ripe for growth in diagnostics and therapeutics.Dublin, Nov. 19, 2025 (GLOBE NEWSWIRE) -- The "Human Microbiome Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" report has been added to ResearchAndMarkets's offering.
The Human Microbiome Market was valued at USD 0.62 Billion in 2024, and is expected to reach USD 1.52 Billion by 2030, rising at a CAGR of 16.28%
The Global Human Microbiome Market is experiencing a significant transformation, fueled by growing scientific recognition of the microbiome's impact on human health and disease, along with increasing investments from pharmaceutical and biotechnology firms. This market encompasses the development of diagnostics, therapeutics, and healthcare solutions aimed at leveraging or modifying the human microbiota comprising trillions of microorganisms that inhabit the human body for improved medical outcomes.
![]()
Key Market Drivers
Increased Application in Cancer Treatment
Research has demonstrated that the human microbiome plays a crucial role in modulating immune responses, which directly impacts the efficacy of immunotherapies and chemotherapy. Certain gut microbiota strains have been found to enhance the effectiveness of immune checkpoint inhibitors, leading to improved patient outcomes. Biotech firms and pharmaceutical companies are investing in microbiome-derived drugs that can be used as adjunct therapies to traditional cancer treatments. These therapies aim to reduce treatment-related toxicity, improve drug absorption, and enhance immune system resilience.
The surge in clinical trials exploring microbiome-based interventions for cancer treatment is accelerating market growth. Studies are investigating how gut microbiota composition influences cancer progression and response to therapy. Rajiv Gandhi Cancer Institute and Research Centre (RGCIRC) has established itself as a premier clinical trial site, earning recognition from leading global cancer research institutions and pharmaceutical companies. With a track record of participation in over 300 national and international clinical trials, the center plays a pivotal role in advancing oncology research and innovative cancer therapies across diverse cancer types. Leading biotech firms and research institutions are forming strategic partnerships to develop microbiome-based cancer solutions. Increased funding from government agencies and private investors is driving innovation in microbiome therapeutics.
The integration of microbiome profiling into precision oncology is enabling personalized treatment plans tailored to individual patients. AI-driven microbiome analysis is helping identify biomarkers that predict cancer treatment responses. Regulatory bodies are recognizing the potential of microbiome-based therapies, leading to faster approvals and standardization efforts. The market is witnessing expansion into emerging economies, where cancer prevalence is rising.
Key Market Challenges
Scientific Complexity and Limited Understanding of Microbiome Functions
One of the most fundamental challenges impeding market growth is the incomplete and complex understanding of the human microbiome's structure, function, and interactions with host physiology. Despite major research advancements, scientists still face difficulties in: Differentiating between beneficial, neutral, and harmful microbes, Understanding causal relationships between microbiome imbalances and specific diseases, Establishing universal biomarkers or reference ranges for "healthy" microbiota.
This scientific uncertainty limits the ability of researchers and companies to design effective, targeted, and reproducible microbiome-based therapies. Moreover, it complicates clinical trial design and makes it harder to validate efficacy, slowing product development and investor confidence.
Key Market Trends
Shift Toward Personalized Microbiome-Based Therapies
The most significant trends fueling market growth is the rapid evolution of personalized medicine powered by microbiome insights. As scientific understanding of the human microbiome deepens, it is becoming increasingly clear that microbial compositions vary significantly across individuals. This has led to a paradigm shift from generalized probiotic or therapeutic approaches toward personalized microbiome interventions, including: Tailored probiotics and synbiotics based on individual gut flora, Microbiome profiling and diagnostics to guide treatment decisions, Customized dietary recommendations to optimize gut health and disease prevention.
This trend aligns with the broader healthcare movement toward precision medicine, offering more effective, safer, and targeted interventions. As genomic sequencing and microbiome mapping technologies become more accessible and affordable, personalized microbiome-based therapies are poised to redefine patient care.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 182 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value (USD) in 2024 | $0.62 Billion |
| Forecasted Market Value (USD) by 2030 | $1.52 Billion |
| Compound Annual Growth Rate | 16.2% |
| Regions Covered | Global |
Report Scope:
Key Market Players
Enterome Bioscience SA Yakult Honsha Co. Ltd. 4 D Pharma Evelo Biosciences Seres Therapeutics Inc. Vedanta Biosciences Second Genome Inc. Quantibiome Rebiotix Inc. Microbiome Therapeutics LLC
Human Microbiome Market, By Product:
Prebiotics Probiotics Medical Food Supplements Others
Human Microbiome Market, By Application:
Human Microbiome Market, By Disease:
Infectious Disease Endocrine and Metabolic Disorders Gastrointestinal Diseases Cancer Others
Human Microbiome Market, By Technology:
Genomics Proteomics Metabolomics
Human Microbiome Market, By Type:
FMT Peptide Live Biotherapeutic Product Others
Human Microbiome Market, By Region:
North America United States Canada Mexico Europe France United Kingdom Italy Germany Spain Asia-Pacific China India Japan Australia South Korea South America Brazil Argentina Colombia Middle East & Africa South Africa Saudi Arabia UAE
For more information about this report visit
About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
CONTACT:
CONTACT:
Laura Wood,Senior Press Manager...
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
![]()
MENAFN19112025004107003653ID1110365785
Comments
No comment